GlassScriptPhysician profile
Stephen P Bazeley
NPI 1336143049
$1,150.63
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $164 · 2021: $218 · 2022: $320 · 2023: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $255.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $170.26 | 2021-2023 | Vraylar, Ubrelvy |
| Pfizer INC. | $119.71 | 2019-2022 | |
| Novo Nordisk INC | $109.88 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.05 | 2019-2023 | Jardiance |
| Amarin Pharma, INC. | $71.90 | 2019-2022 | |
| Amgen INC. | $47.94 | 2020-2023 | Prolia, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $43.51 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $42.88 | 2021-2023 | |
| Lilly USA, LLC | $40.73 | 2022 | |
| Allergan, INC. | $37.73 | 2019-2020 | |
| Glaxosmithkline, LLC. | $33.12 | 2022-2023 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.02 | 2019-2023 | Xifaxan |
| Astellas Pharma US INC | $32.12 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $31.15 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $27.36 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $24.21 | 2022 | |
| Lundbeck LLC | $20.49 | 2023 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $19.97 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.67 | 2022 | |
| Sumitomo Pharma America, INC. | $16.36 | 2023 | Gemtesa |
| Exact Sciences Corporation | $15.74 | 2023 | Cologuard Collection Kit |
| Bausch Health US, LLC | $15.23 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.08 | 2023 | Quviviq |
| Glenmark Therapeutics INC. | $15.00 | 2019 | |
| Eisai INC. | $14.83 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.46 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.83 | 2020 | |
| Corium, LLC | $11.54 | 2023 | Azstarys |
| Astrazeneca Pharmaceuticals LP | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Bazeley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.